1198439-05-2

Basic information

• Product Name: 1-ISOPROPYL-1H-IMIDAZOLE-2-CARBOXYLIC ACID
• Synonyms: 1-ISOPROPYL-1H-IMIDAZOLE-2-CARBOXYLIC ACID
• CAS NO: 1198439-05-2
• Molecular Formula: C7H10N2O2
• Molecular Weight: 154.1665
• Mol File: 1198439-05-2.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-ISOPROPYL-1H-IMIDAZOLE-2-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 1-ISOPROPYL-1H-IMIDAZOLE-2-CARBOXYLIC ACID(1198439-05-2)
• EPA Substance Registry System: 1-ISOPROPYL-1H-IMIDAZOLE-2-CARBOXYLIC ACID(1198439-05-2)

Safety Data

• Hazardous Substances Data: 1198439-05-2(Hazardous Substances Data)

Usage

General Description

1-ISOPROPYL-1H-IMIDAZOLE-2-CARBOXYLIC ACID, also known as IICA, is a chemical compound with a molecular formula C8H12N2O2. It is a derivative of imidazole and is commonly used in the pharmaceutical industry as a building block for the synthesis of various pharmaceutical compounds. IICA has been identified as a potential inhibitor of the enzyme protein kinase CK2, which is implicated in a variety of cellular processes and diseases such as cancer, making it a potential target for drug development. Additionally, IICA has shown promise as an anti-inflammatory agent and has potential applications in the development of new drugs for the treatment of various diseases.

Upstream product

• 2017188-77-9 1-isopropyl-1H-imidazole-2-carboxylic acid ethyl ester 

Relevant articles and documents

Structure-guided optimization of 1H-imidazole-2-carboxylic acid derivatives affording potent VIM-Type metallo-β-lactamase inhibitors

Production of metallo-β-lactamases (MBLs) in bacterial pathogens is an important cause of resistance to the ‘last-resort’ carbapenem antibiotics. Development of effective MBL inhibitors to reverse carbapenem resistance in Gram-negative bacteria is still needed. We herein report X-ray structure-guided optimization of 1H-imidazole-2-carboxylic acid (ICA) derivatives by considering how to engage with the active-site flexible loops and improve penetration into Gram-negative bacteria. Structure-activity relationship studies revealed the importance of appropriate substituents at ICA 1-position to achieve potent inhibition to class B1 MBLs, particularly the Verona Integron-encoded MBLs (VIMs), mainly by involving ingenious interactions with the flexible active site loops as observed by crystallographic analyses. Of the tested ICA inhibitors, 55 displayed potent synergistic antibacterial activity with meropenem against engineered Escherichia coli strains and even intractable clinically isolated Pseudomonas aeruginosa producing VIM-2 MBL. The morphologic and internal structural changes of bacterial cells after treatment further demonstrated that 55 crossed the outer membrane and reversed the activity of meropenem. Moreover, 55 showed good pharmacokinetic and safety profile in vivo, which could be a potential candidate for combating VIM-mediated Gram-negative carbapenem resistance.

Application of 1-substituted-1H-imidazole-2-carboxylic acid compounds in preparation of metal beta-lactamase inhibitors

The invention relates to application of 1-substituted-1H-imidazole-2-carboxylic acid compounds in preparation of metal beta-lactamase inhibitors, and particularly discloses application of compounds shown in a formula I in preparation of metal beta-lactamase inhibitors or antibacterial combined medicines. Experiments prove that the compounds provided by the invention can be used for effectively inhibiting the activity of various MBL enzymes including VIM-2, NDM-1, IMP-1, VIM-1 and VIM-5; the compounds, especially the compounds 11, 13, 14, 29, 30, 34, 37 and 40, have an IC50 value of 2.13 [mu] Mor less on the VIM-2 type MBL enzymes, have a more significant inhibition effect than positive control drugs, and have very good potential in the preparation of MBL enzyme inhibitors. Meanwhile, thecompounds disclosed by the invention are combined with beta-lactam antibiotics, so that metal beta-lactamase generated by drug-resistant bacteria can be effectively inhibited, the antibacterial activity of the antibiotics is enhanced, and the compounds have a very good application prospect in preparation of antibacterial combined medicines.